Skip to main content
OpenTrials
Completed

NCT Number: NCT03955120

Validation of the Dayzz Digital Sleep Training App in Insomnia and Sleep Apnea

The prevalence of sleep disorders has achieved epidemic proportions in Western countries. Despite this, assessment and treatment of sleep disorders remains infrequent, unattainable, and often costly. Dayzz is aware of the need for easily accessible, user-friendly, and affordable treatment strategies for known sleep conditions. This research proposes a randomized controlled outcome study aimed to validate a, digitized, cost-effective mobile app which assesses and manages insomnia and CPAP adherence in persons with sleep apnea. The app's sleep training protocols recommend life-style and behavioral changes and tracks these changes with the aim of improving sleep and well-being. In this study, the dayzz app digital treatment protocol will be compared to the standard treatment for these sleep conditions by a sleep professional.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 21-65 years of age referred to the Carmel Hospital sleep clinic and diagnosed by the clinic physician with either Sleep Apnea (referred for CPAP treatment) or Insomnia.

Exclusion criteria

  • Patient age <21 years.
  • Patient who is not a member of Clalit Healthcare services.
  • Persons with insufficient control of the English language required for adequate use of app.
  • Persons with insufficient experience/knowledge and/or use of digital apps/smartphones.
  • Persons with serious medical or psychiatric conditions.
  • Women who are pregnant or breastfeeding.
  • Nighttime shift-workers.
  • Persons who are unable to provide consent due to mental incapacity.
  • Persons referred for evaluation of sleep by Ministry of Transportation (for licensing purposes).
  • Persons with comorbid insomnia and sleep apnea

Treatment and study plan

Dayzz mobile sleep training

Behavioral
  • The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.
  • Each app user is matched with a "sleep trainer" who will communicate with them via a "chat" option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.
  • Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study.

Treatment as Usual

Other

Standard medical care for specific sleep condition

Primary outcomes

  1. Total sleep time (minutes)

    Time frame: 3 months to 1 year

    sleep duration in minutes per night (based on nightly sleep diary)

  2. Sleep onset latency (minutes)

    Time frame: 3 months to 1 year

    Number of minutes to fall asleep per night (based on nightly sleep diary)

  3. Wake after sleep onset (minutes)

    Time frame: 3 months to 1 year

    Number of minutes awake in total per night (based on nightly sleep diary)

  4. Sleep efficiency (percent)

    Time frame: 3 months to 1 year

    (Number of minutes asleep per night/number of minutes in bed per night)*100 (based on sleep diary data)

  5. Sleep quality

    Time frame: 3 months to 1 year

    Likert scale of sleep quality between 1 and 10 (based on sleep diary report)

  6. Nightly CPAP use

    Time frame: 3 months to 1 year

    Minutes of wearing the CPAP mask per night (based on sleep diary report)

  7. Excessive daytime sleepiness

    Time frame: 3 months to 1 year

    The Epworth Sleepiness Scale (ESS): The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity or their 'daytime sleepiness'.

  8. Sleep symptom screening questionnaire

    Time frame: 3 months to 1 year

    The Dayzz Sleep Questionnaire is a digitized screening measure that assesses sleep quantity and quality and presence/risk for specific sleep disorders. It is composed of some self-rated items, assessing sleep amounts, sleep quality, excessive sleepiness, and risk factors for sleep-related breathing disorders, symptoms of insomnia and sleep/wake circadian rhythms. The questions are based on the International Classification of Sleep Disorders (3rd Edition; American Academy of Sleep Medicine) diagnostic criteria for four common categories of sleep disorders: Insomnia, Insufficient Sleep Syndrome, Sleep Apnea Disorders, and Circadian Rhythm Sleep-Wake Disorders.

  9. Insomnia severity

    Time frame: 3 months to 1 year

    The Insomnia Severity Index (ISI) is a well-validated 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia over the past month (Morin, 1993). The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Secondary outcomes

  1. Work productivity

    Time frame: 3 months to 1 year

    The Work Productivity and Activity Impairment Questionnaire-Specific Health problem (WPAI:SHP): The WPAI is a patient-reported quantitative assessment of the amount of absenteeism, presenteeism and daily activity impairment attributable to a specific health problem (Reilly et al, 1993). WPAI:SHP outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

  2. Insomnia-related quality of life

    Time frame: 3 months to 1 year

    The Glasgow Sleep Impact Index (GSII). Administered only to the insomnia sample. The GSII is a self-report measure which asks patients to generate, and assess, three domains of measure insomnia-related quality of life impairment. These three patient-generated areas of impairment are ranked in order of concern (1-3; i.e. 1=the most concerning impairment), and then rated on a visual analogue scale with respect to impact in the past two weeks. Patients re-rate these specified areas of impairment, post-intervention, permitting both individual and group-level analyses.

  3. Sleep Apnea-related Quality of Life-Short form (SAQLI-SF)

    Time frame: 3 months to 1 year

    The SAQLI- SF (for sleep apnea sample only) measures the effects of sleep apnea on a person's quality of life. The questions represent four quality of life domains: Daily Activities, Social Interactions, Emotions,and Symptoms. Two total scores will be generated, which reflect the pre- and post-treatment quality of life. The total scores range between 1-14, with higher values representing poorer outcomes. No subscale scores are generated.

  4. The WHO-5 Well-being Index (WHO-5)

    Time frame: 3 months to 1 year

    The WHO-5 Well-being Index (WHO-5) is a short, self-administered questionnaire measuring psychological well-being. It covers 5 positively worded items, related to positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interests (being interested in things). Each of the five items is rated on a 6-point Likert scale from 0 (= not present) to 5 (= constantly present). Scores are summated, with raw score ranging from 0 to 25. Then the scores are transformed to 0-100 by multiplying by 4 which provides the total score, with higher scores meaning better well-being. The scale does not generate subscale scores.

Sponsors and collaborators

Lead sponsor

Dayzz Live Well Ltd.

Industry

Collaborators

  • Israel Innovation Authority

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
May 17, 2019
Registry last updated
Aug 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.